市場調查報告書
商品編碼
1020447

非類固醇消炎劑(NSAID)市場-成長,趨勢,COVID-19的影響,及預測(2021∼2026年)

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

研究中的非類固醇消炎劑(NSAID)的市場規模在預測期間內預計將以年複合成長率5.2%擴大。

非類固醇消炎劑(NSAID)是最常用的藥物之一。這些主要用於治療疼痛和炎症。慢性疼痛和炎症的負擔不斷增加,推動了對非甾體抗炎藥的需求。NSAID 還廣泛用於治療慢性炎症性疾病,例如類風濕性關節炎和脊柱關節炎。它們比其他藥物更受歡迎,因為它們價格低廉,並且有助於控制類風濕性關節炎的慢性疼痛、炎症和腫脹。在全球範圍內,類風濕性關節炎 (RA) 的患病率和發病率都有所增加,預計非甾體抗炎藥市場在預測期內將出現顯著增長。然而,使用非甾體抗炎藥引起的副作用是市場增長的主要障礙。

本報告提供非類固醇消炎劑(NSAID)市場相關調查,提供市場概要,以及給藥途徑,各用途,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場推動因素
    • 增加慢性疼痛和炎症的負擔
    • 非類固醇抗炎藥優於其他止痛藥
  • 市場阻礙因素
    • 藥物研發和上市成本高
    • NSAIDs 的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各給藥途徑
    • 口服
    • 非口服
  • 各用途
    • 關節炎
    • 偏頭痛
    • 眼科疾病
    • 其他
  • 各流通管道
    • 醫院藥局
    • 零售藥局
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Pfizer Inc.
    • GlaxoSmithKline Plc
    • Johnson &Johnson
    • Bayer AG
    • Sanofi SA
    • Horizon Therapeutics plc
    • Sun Pharmaceutical Industries Ltd
    • Iroko Pharmaceuticals Inc.
    • Reckitt Benckiser Group PLC
    • Assertio Therapeutics, Inc.

第7章 市場機會及趨勢

目錄
Product Code: 72185

The Non-steroidal Anti-inflammatory Drugs (NSAIDs) market studied is expected to grow with an estimated CAGR of 5.2%, over the forecast period.

COVID-19 has become a major public health problem. In past, there have been inappropriate warnings against the use of these NSAIDs drugs for Covid patients with an increased risk of adverse effects. This led to general confusion among patients and the medical community. The WHO declared in April 2020 that there is no evidence of an increased risk of death with the use of NSAIDs in Covid-19. According to an article by Alessandro Giollo (2021) titled "Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)" it is recommended to patients with chronic inflammatory arthritis to continue the use of NSAIDs until more evidence is available for the risk of using such drugs. Thus the global market of NSAIDs will have a large impact of Covid-19 on the use and prescription of NSAIDs drugs and the future depends on the results of various trials that are ongoing for understanding the effect of NSAIDs on Covid patients.

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs. These are largely used in the treatment of pain and inflammation. The rising burden of chronic pain and inflammation is driving the demand for NSAIDs. NSAIDs are also used broadly for the treatment of chronic inflammatory disorders such as rheumatoid arthritis and spondyloarthritis. They are prefered over other drugs because they're inexpensive and they help manage the chronic pain, inflammation, and swelling that are characteristic of rheumatoid arthritis. Globally there is an increase in prevalence and incidence rates of rheumatoid arthritis (RA). According to an article by Khalid Almutairi (2021) titled "The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review", The global prevalence of RA in 2019 was 460 per 100,000 population, with variations due to geographical location. According to the Centers for Disease Control and Prevention, by 2040, an estimated 78 million (26%) US adults aged 18 years or older are projected to get diagnosed by arthritis. In view of all the mentioned facts, the NSAIDs Market is expected to witness a significant growth over the forecast period.

However, side effcet caused by use of NSAIDs is a major barrier in the market growth. The major therapeutic actions of NSAIDs are produced by its ability to inhibit cyclooxygenase enzymes (COX-1 and COX-2). The desired effect of NSAIDs' anti-inflammatory, antipyretic and analgesic response are because of its COX-2 inhibition; while COX-1 inhibition plays a major role in the undesired side effects such as Gastrointestinal and renal toxicities. This is expected to negatively impact the non-steroidal anti-inflammatory drugs market growth.

Key Market Trends

The Arthritis Segment Is Expected To Grow Faster And Dominate The Market Over The Forecast Period

The arthritis segment is anticipated to hold the major share over the forecast period. According to data from the Centers for Disease Control and Prevention, in the United States, by 2040, an estimated 78.4 million (25.9% of the projected total adult population) adults aged 18 years and older will have doctor-diagnosed arthritis. It is also observed that arthritis prevalence increases with age. Severe arthritis is a barrier to physical activity, which is directly associated with obesity, cardiovascular disease, diabetes, and other functional limitations.

NSAIDs are commonly used in patients with chronic inflammatory arthritis. Increasing incidence of arthritis is predicted to accelerate the market for NSAIDs. They are effective anti-inflammatory and analgesic due to their ability to inhibit the biosynthesis of prostaglandins at the level of the cyclooxygenase enzyme. Several drugs of NSAIDs class are in the market and many more are in pipeline. In January 2021, the U.S. Food and Drug Administration approved a generic version of Pfizer's Celebrex (celecoxib), an oral medication used to treat inflammation and pain caused by ankylosing spondylitis and other disorders. The generic drug is also indicated to treat osteoarthritis, rheumatoid arthritis, juvenile arthritis, acute pain, and primary dysmenorrhea (pain caused by menstruation). Based on the above-mentioned facts, it is expected that the NSAIDs drug segment will grow over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America holds the major market share in the NSAIDs market and is expected to dominate the overall market throughout the forecast period. NSAIDs are frequently used to treat conditions such as inflammatory arthritis, migraine pain and others. NSAIDs are relatively inexpensive and are commonly the first line of medication used to relieve pain and reduce inflammation.

As per the Migraine Research Foundation (2020), migraine is a highly prevalent neurological disease, affecting nearly 40 million men, women and children in the U.S. While most sufferers experience attacks once or twice a month, more than 4 million people have chronic daily migraine, with at least 15 migraine days per month. The major driver for this trend is the increasing burden of inflammatory diseases​. According to an article by Rebecca Burch (2021) titled "The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys", the age-adjusted prevalence was 15.9% across all adults. While the burden of arthritis is estimated to be around 63 million in 2020 as projected by Centers for Disease Control and Prevention.

Market players in the country are continuously focusing on the development of novel drugs to tackle these indications using NSAIDs, and they are also adopting various strategies to develop better drugs with reduced side effects. Thus, this is likely to drive the market in the country. For instance, in February 2020, the FDA approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) for the temporary relief of arthritis pain. In view of these recent developments and other above-mentioned factors the NSAIDs market is expected to get a boost in the region.

Competitive Landscape

The NSAIDs market is highly competitive with several players across the globe. In terms of market share, few of the major players currently dominate the market. With the increase in research and development activity, many regional players are expected to contribute in the NSAIDs market over the forecast period. Some of the major players of the market are Pfizer Inc., GlaxoSmithKline Plc, Johnson & Johnson, Bayer AG, Sanofi S.A., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Iroko Pharmaceuticals Inc., Reckitt Benckiser Group PLC, Assertio Therapeutics, Inc. and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Chronic Pain and Inflammation
    • 4.2.2 Preference of NSAIDs over Other Class of Pain Relievers
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Drug Development and Launches
    • 4.3.2 Side Effects of NSAIDs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Route of Administration
    • 5.1.1 Oral
    • 5.1.2 Parenteral
  • 5.2 By Application
    • 5.2.1 Arthritis
    • 5.2.2 Migraine
    • 5.2.3 Ophthalmic Diseases
    • 5.2.4 Other Applications
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Others Distribution Channels
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer Inc.
    • 6.1.2 GlaxoSmithKline Plc
    • 6.1.3 Johnson & Johnson
    • 6.1.4 Bayer AG
    • 6.1.5 Sanofi S.A.
    • 6.1.6 Horizon Therapeutics plc
    • 6.1.7 Sun Pharmaceutical Industries Ltd
    • 6.1.8 Iroko Pharmaceuticals Inc.
    • 6.1.9 Reckitt Benckiser Group PLC
    • 6.1.10 Assertio Therapeutics, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS